Encompass Health Corp. (NYSE: EHC) FY2025 revenue ~$5.65-5.85B (+8-12%) with adj. EPS ~$4.85-5.30 reflecting continued post-2024 ~$5.65-5.85B aggregate Inpatient Rehabilitation Facility (IRF) revenue (~100% aggregate revenue mix; selected primary post-January 2023 Enhabit Home Health & Hospice spinoff IRF-focused pure-play; selected ~165+ aggregate IRF hospitals + selected ~10+ aggregate annual de novo IRF hospital openings) under continued President + CEO Mark Tarr since 2017 (~8-year tenure as Encompass Health CEO; selected post-January 2023 Enhabit Home Health & Hospice spinoff). One of the largest US Inpatient Rehabilitation Facility (IRF) hospital operators. Founded 1984 as HealthSouth Corporation in Birmingham Alabama by Richard Scrushy (~41-year heritage); selected post-2018 HealthSouth → Encompass Health rebrand; selected post-1986 NYSE listing; selected post-January 2023 Enhabit spinoff; selected post-2017 Mark Tarr CEO appointment. Headquartered in Birmingham Alabama; ~46,000+ employees globally with ~$5.65-5.85B revenue. One primary business: Inpatient Rehabilitation Facility (~100% ~$5.65-5.85B). Geographic mix: US ~100%; selected primary South + Southeast + Mid-Atlantic + Midwest + Texas + Florida. IRF cycle: ~$5.65-5.85B IRF revenue; ~165+ aggregate IRF hospitals; ~10,000+ aggregate licensed beds; ~225,000-235,000 aggregate annual discharges; ~75-80% aggregate occupancy; ~+5-8% aggregate same-hospital admission growth; ~+5-7% aggregate net revenue per discharge growth. De novo hospital pipeline + post-January 2023 Enhabit spinoff focus: ~10+ aggregate annual de novo IRF hospital openings; ~30+ aggregate JV partner hospitals; ~$280-330M aggregate annual de novo + acquisition CapEx. President + CEO Mark Tarr since 2017 (~8-year tenure); CFO Doug Coltharp. Capital return: ~$0.68 annual dividend FY2025 (~+10-15% growth post-2024 dividend acceleration; ~5-year continuous dividend track post-2020); ~$200-300M aggregate FY2024-2025 buyback program (~$100-150M aggregate FY2025); aggregate capital return ~$170-220M FY2025; net leverage ratio ~3.0-3.5x; non-investment grade Ba2/BB+ credit rating. FY2026 thesis: IRF cycle + De novo hospital pipeline + selected post-January 2023 Enhabit spinoff focus + ~$0.68 annual dividend + ~5-year continuous dividend track + ~$170-250M aggregate annual capital return + selected potential post-2024 dividend acceleration. Risks: Select Medical Holdings + HCA Healthcare + Tenet Healthcare + Universal Health Services competition, CMS IRF reimbursement, Medicare Advantage payer mix shift, IRF compliance threshold.

[EHC] Encompass Health Thesis 2026: IRF Cycle Drives De Novo Hospital Pipeline

Key Takeaways

EHC FY2025 revenue ~$5.65-5.85B (+8-12% YoY) with adj. EPS ~$4.85-5.30 reflecting continued post-2024 ~$5.65-5.85B aggregate Inpatient Rehabilitation Facility (IRF) revenue (~100% aggregate revenue mix; selected primary post-January 2023 Enhabit Home Health & Hospice spinoff IRF-focused pure-play; selected ~165+ aggregate IRF hospitals + selected ~10+ aggregate annual de novo IRF hospital openings) under continued President + CEO Mark Tarr since 2017 (~8-year tenure as Encompass Health CEO; selected post-January 2023 Enhabit Home Health & Hospice spinoff).
IRF cycle (Inpatient Rehabilitation Facility): ~$5.65-5.85B IRF revenue (~100% revenue mix); selected ~165+ aggregate IRF hospitals + selected ~10,000+ aggregate licensed beds + selected primary post-stroke + post-orthopedic + post-cardiac rehabilitation; selected ~225,000-235,000 aggregate annual discharges + selected various aggregate ~+5-8% aggregate same-hospital admission growth + selected various aggregate ~+5-7% aggregate net revenue per discharge growth.
De novo hospital pipeline + selected post-January 2023 Enhabit spinoff focus: selected continued post-2024 ~10+ aggregate annual de novo IRF hospital openings + selected continued post-January 2023 Enhabit Home Health & Hospice spinoff focus on IRF-focused pure-play + selected various aggregate ~$280-330M aggregate annual de novo + acquisition CapEx + selected ~30+ aggregate JV partner hospitals + selected various aggregate post-stroke + post-orthopedic + post-cardiac rehabilitation demand tailwind.
Capital return + balance sheet: ~~$0.68 annual dividend FY2025 (~~$0.17/quarter; ~+10-15% growth post-2024 dividend acceleration; ~5-year continuous dividend track post-2020); ~~$200-300M aggregate FY2024-2025 buyback program (~~$100-150M aggregate FY2025); aggregate capital return ~$170-220M FY2025; net leverage ratio ~3.0-3.5x net debt-to-adj. EBITDA; non-investment grade Ba2/BB+ credit rating.
FY2026 thesis catalysts: IRF cycle (Inpatient Rehabilitation Facility) + De novo hospital pipeline + selected post-January 2023 Enhabit spinoff focus + ~$0.68 annual dividend + ~5-year continuous dividend track + ~$170-250M aggregate annual capital return + selected potential post-2024 dividend acceleration.

Company Background

Encompass Health Corp. (NYSE: EHC) is one of the largest US Inpatient Rehabilitation Facility (IRF) hospital operators, founded 1984 as HealthSouth Corporation in Birmingham Alabama by Richard Scrushy (~41-year heritage; selected pioneer US Inpatient Rehabilitation Facility); selected post-2018 HealthSouth → Encompass Health rebrand. Selected post-1986 NYSE listing transition; selected post-1986-2024 selected various ~$15B+ aggregate cumulative tuck-in M&A platform expansion (selected post-1980s-2010s selected various ReLife + Surgical Health + selected various consolidations; selected post-2014 ~$700M+ EHHI Holdings home health + hospice acquisition; selected post-2024 selected various tuck-in M&A); selected post-January 2023 ~$3B+ aggregate Enhabit Home Health & Hospice spinoff separation creating selected IRF-focused pure-play; selected post-2017 Mark Tarr CEO appointment (succeeded post-2017 Jay Grinney retirement); HQ Birmingham Alabama; ~46,000+ employees globally.

EHC operates 1 primary business: Inpatient Rehabilitation Facility (IRF) ~~100% revenue (~~$5.65-5.85B — selected primary post-stroke + post-orthopedic + post-cardiac + selected various complex medical rehabilitation). Geographic mix: US ~~100% revenue (~~$5.65-5.85B); selected primary South + Southeast + Mid-Atlantic + Midwest + Texas + Florida + selected various US Inpatient Rehabilitation Facility footprint. Selected ~165+ aggregate IRF hospitals + selected ~10,000+ aggregate licensed beds.

Capital return: ~~$0.68 annual dividend FY2025 (~~$0.17/quarter; ~+10-15% growth post-2024 dividend acceleration; ~5-year continuous dividend track post-2020); ~~$200-300M aggregate FY2024-2025 buyback program (~~$100-150M aggregate FY2025); aggregate capital return ~$170-220M FY2025; net leverage ratio ~3.0-3.5x net debt-to-adj. EBITDA; non-investment grade Ba2/BB+ credit rating.

IRF Cycle (Inpatient Rehabilitation Facility)

The IRF cycle is EHC's foundation thesis: ~$5.65-5.85B IRF revenue (~100% revenue mix) + selected ~165+ aggregate IRF hospitals + selected ~10,000+ aggregate licensed beds + selected primary post-stroke + post-orthopedic + post-cardiac rehabilitation + selected ~225,000-235,000 aggregate annual discharges + selected various aggregate ~+5-8% aggregate same-hospital admission growth + selected various aggregate ~+5-7% aggregate net revenue per discharge growth. Selected primary EHC IRF platform: ~165+ aggregate IRF hospitals + ~10,000+ aggregate licensed beds + selected various aggregate ~30+ aggregate JV partner hospitals + selected various aggregate ~75-80% aggregate occupancy.

FY2025 IRF dynamics ($5.65-5.85B aggregate IRF revenue): selected continued post-2024 ~+5-8% aggregate same-hospital admission growth + ~+5-7% aggregate net revenue per discharge growth + ~225,000-235,000 aggregate annual discharges + selected various aggregate ~75-80% aggregate occupancy + selected various aggregate ~10+ aggregate annual de novo IRF hospital openings + selected various aggregate ~5+ aggregate annual JV + acquisition. Selected post-2024 ~$0.40-0.55 incremental annual EPS contribution as IRF cycle (post-stroke + post-orthopedic + post-cardiac rehabilitation demand) drives incremental margin + IRF revenue.

FY2026 catalyst: continued IRF cycle + ~$0.40-0.55 incremental annual EPS contribution under continued President + CEO Mark Tarr leadership (~8-year tenure). Selected aggregate ~$5.95-6.20B aggregate IRF revenue + selected various ~+5-8% aggregate same-hospital admission growth + ~+5-7% aggregate net revenue per discharge growth + ~+5-7% aggregate annual discharge growth (selected ~10+ aggregate annual de novo IRF hospital openings) + selected various aggregate ~75-80% aggregate occupancy. Risks: Select Medical Holdings + HCA Healthcare (HealthSouth-Mason) + Tenet Healthcare + Universal Health Services + selected various aggregate IRF + selected various aggregate Skilled Nursing Facility (SNF) + Long-Term Care Hospital (LTCH) + Home Health + selected various aggregate competitive displacement + Centers for Medicare & Medicaid Services (CMS) IRF reimbursement (selected various aggregate IRF Prospective Payment System (PPS) + selected various aggregate Medicare Advantage (MA) + selected various aggregate IRF compliance threshold).

De Novo Hospital Pipeline + Post-January 2023 Enhabit Spinoff Focus

The de novo hospital pipeline + post-January 2023 Enhabit spinoff focus is EHC's primary growth thesis: selected continued post-2024 ~10+ aggregate annual de novo IRF hospital openings + selected continued post-January 2023 Enhabit Home Health & Hospice spinoff focus on IRF-focused pure-play + selected various aggregate ~$280-330M aggregate annual de novo + acquisition CapEx + selected ~30+ aggregate JV partner hospitals + selected various aggregate post-stroke + post-orthopedic + post-cardiac rehabilitation demand tailwind.

FY2025 de novo + JV dynamics: ~10+ aggregate annual de novo IRF hospital openings + selected various aggregate JV + acquisition + ~$280-330M aggregate annual de novo + acquisition CapEx + selected various aggregate ~30+ aggregate JV partner hospitals + selected various aggregate post-stroke + post-orthopedic + post-cardiac rehabilitation. Selected post-2024 ~$0.10-0.20 incremental annual EPS contribution as De novo hospital pipeline + selected post-January 2023 Enhabit spinoff focus drives incremental IRF margin + revenue.

FY2026 catalyst: continued De novo hospital pipeline + ~$0.10-0.20 incremental EPS contribution. Selected aggregate ~10-12 aggregate annual de novo IRF hospital openings + selected various aggregate ~$280-350M aggregate annual de novo + acquisition CapEx + selected ~175+ aggregate IRF hospitals + selected ~10,500-11,000 aggregate licensed beds. Risks: Select Medical Holdings + HCA Healthcare + Tenet Healthcare + Universal Health Services + selected various aggregate IRF + selected various aggregate competitive displacement + selected various aggregate de novo + JV + acquisition integration considerations + Certificate-of-Need (CON) state regulatory considerations.

Capital Return + Dividend Track

Capital return + dividend track: ~~$0.68 annual dividend FY2025 (~~$0.17/quarter; ~+10-15% growth post-2024 dividend acceleration; ~5-year continuous dividend track post-2020) + ~~$200-300M aggregate FY2024-2025 buyback program (~~$100-150M aggregate FY2025) + aggregate capital return ~$170-220M FY2025 + net leverage ratio ~3.0-3.5x net debt-to-adj. EBITDA + non-investment grade Ba2/BB+ credit rating.

FY2026 catalyst: continued ~~$0.68-0.80 aggregate dividend (~~+15-20% aggregate selected dividend acceleration) + selected continued ~$100-150M aggregate annual buybacks + selected continued post-2024 selected various aggregate ~3.0-3.5x net leverage. Selected ~5-year continuous dividend track + selected post-2024 dividend acceleration + selected ~3.0-3.5x net leverage support continued capital return + de novo + acquisition + tuck-in M&A discipline. Selected aggregate ~$170-250M aggregate annual capital return FY2026.

Key Core Metrics

FY2025 revenue ~$5.65-5.85B (+8-12% YoY) vs $5.21B FY2024; adj. EPS ~$4.85-5.30
1 segment: Inpatient Rehabilitation Facility (IRF) ~100% (post-January 2023 Enhabit spinoff)
Geographic mix: US ~100%; selected primary South + Southeast + Mid-Atlantic + Midwest + Texas + Florida
~165+ aggregate IRF hospitals; ~10,000+ aggregate licensed beds
~225,000-235,000 aggregate annual discharges; ~75-80% aggregate occupancy
~5-8% aggregate same-hospital admission growth; ~5-7% aggregate net revenue per discharge growth
~10+ aggregate annual de novo IRF hospital openings; ~30+ aggregate JV partner hospitals
~98-100M diluted shares; ~$170-220M total capital return FY2025
~$0.68 annual dividend FY2025 (~5-year continuous dividend track post-2020)
~~$200-300M aggregate FY2024-2025 buyback program (~~$100-150M aggregate FY2025)
Net leverage ratio ~3.0-3.5x net debt-to-adj. EBITDA
Non-investment grade Ba2/BB+ credit rating
President + CEO Mark Tarr (since 2017, ~8-year tenure); CFO Doug Coltharp
Selected post-January 2023 ~$3B+ Enhabit Home Health & Hospice spinoff

Market Evaluation

EHC trades as an IRF-focused pure-play hospital operator levered to IRF cycle (post-stroke + post-orthopedic + post-cardiac rehabilitation demand) + de novo hospital pipeline + selected post-January 2023 Enhabit Home Health & Hospice spinoff focus + selected ~5-year continuous dividend track. Bull case: ~$5.65-5.85B IRF revenue + ~165+ aggregate IRF hospitals + ~225,000-235,000 aggregate annual discharges + ~75-80% aggregate occupancy + ~10+ aggregate annual de novo IRF hospital openings + selected post-January 2023 Enhabit spinoff focus + ~$0.68 dividend (~5-year track) drive ~$5.30-5.85 adj. EPS FY2026 (+8-10% YoY). Bear case: Select Medical Holdings + HCA Healthcare + Tenet Healthcare + Universal Health Services competitive displacement + Centers for Medicare & Medicaid Services (CMS) IRF reimbursement severe + Medicare Advantage payer mix shift severe + IRF compliance threshold + sustained ~3.0-3.5x net leverage + selected various aggregate de novo + JV + acquisition integration considerations trigger material EPS compression. Base case: IRF cycle + de novo hospital pipeline + ~5-year continuous dividend track + ~3.0-3.5x net leverage discipline support continued ~$5.30-5.85 adj. EPS + ~$170-250M aggregate capital return FY2026.

IRF Cycle Drives De Novo Hospital Pipeline Deep Dive

Selected continued post-2024 ~$5.65-5.85B aggregate Inpatient Rehabilitation Facility (IRF) revenue (~100% revenue mix; selected primary post-stroke + post-orthopedic + post-cardiac rehabilitation) + selected continued post-2024 ~165+ aggregate IRF hospitals + selected continued post-2024 ~10,000+ aggregate licensed beds + selected continued post-2024 ~225,000-235,000 aggregate annual discharges + selected continued post-2024 ~75-80% aggregate occupancy + selected continued post-2024 ~+5-8% aggregate same-hospital admission growth + selected continued post-2024 ~+5-7% aggregate net revenue per discharge growth + selected continued post-2024 ~10+ aggregate annual de novo IRF hospital openings + selected continued post-2024 ~30+ aggregate JV partner hospitals + selected continued post-January 2023 ~$3B+ Enhabit Home Health & Hospice spinoff focus on IRF-focused pure-play + selected continued post-2024 ~$280-330M aggregate annual de novo + acquisition CapEx + selected ~~$0.68 annual dividend (~~+10-15% growth post-2024 dividend acceleration; ~5-year continuous dividend track post-2020) + selected ~$100-150M aggregate annual buybacks + selected ~3.0-3.5x net leverage drive EHC's primary FY2026 thesis. President + CEO Mark Tarr (~8-year tenure) leadership continues post-2017 CEO appointment focus on IRF cycle + de novo hospital pipeline + selected post-January 2023 Enhabit spinoff focus + capital return discipline + selected continued post-2018 HealthSouth → Encompass Health rebrand. Risks: Select Medical Holdings + HCA Healthcare (HealthSouth-Mason) + Tenet Healthcare + Universal Health Services + selected various aggregate IRF + selected various aggregate Skilled Nursing Facility (SNF) + Long-Term Care Hospital (LTCH) + Home Health + selected various aggregate competitive displacement + Centers for Medicare & Medicaid Services (CMS) IRF reimbursement (selected various aggregate IRF Prospective Payment System (PPS) + selected various aggregate Medicare Advantage (MA) + selected various aggregate IRF compliance threshold) + selected various aggregate Medicare Advantage payer mix shift considerations + selected various aggregate de novo + JV + acquisition integration considerations + Certificate-of-Need (CON) state regulatory considerations + selected post-January 2023 ~$3B+ Enhabit spinoff legacy considerations + sustained ~3.0-3.5x net leverage.